As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...
Hosted on MSN3d
What Is the Difference Between Psychosis and Schizophrenia?Medically reviewed by Dakari Quimby, PhD Psychosis and schizophrenia are related but distinct mental health conditions ...
News Medical on MSN2d
Study reveals immune system changes linked to schizophrenia and treatment resistanceResearchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
The CONNEX program consisted of the randomized, double-blind, placebo-controlled phase 3 CONNEX-1, CONNEX-2, and CONNEX-3 studies ...
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
At 44, I like to think I’m aging gracefully with schizophrenia ... so they hazed me. My symptoms really came out after an incident in which I was duct taped in the fetal position.
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...
Treatment-resistant schizophrenia (TRS) is generally understood as a failure to respond to at least two trials of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback